Martin Knaus

Dr. Martin Knaus

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2019 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
Vito ColellaVito Colella
Vito Colella
MKMartin Knaus
Martin Knaus
OLOlimpia R. Lai
Olimpia R. Lai
CCCarlo Cantile
Carlo Cantile
FAFrancesca Abramo
Francesca Abramo
Domenico OtrantoDomenico Otranto
Domenico Otranto
Several species of nematodes included in the superfamily Metastrongyloidea are recognized agents of parasitic infections in felines. Aelurostrongylus abstrusus is the most prevalent species affecting the respiratory system of domestic cats. The route of infection in cats is supposed to be through ingestion of gastropod intermediate or paratenic hosts. However, because gastropods are not the preferred preys of cats, rodents were suggested to play an important role as paratenic hosts in the biological cycle of A. abstrusus and in the epidemiology of aelurostrongylosis. Two studies were conducted to document histopathological tissue lesions in mice experimentally infected with A. abstrusus third-stage larvae (L3) (Study 1), and to determine larval counts in their organs (Study 2). Additionally, cats were fed with experimentally infected mice to assess their infectivity. Aelurostrongylus abstrusus L3 were recovered from the liver, spleen, brain, skeletal muscle and gastrointestinal tract tissues by artificial digestion, and heart, spleen and brain tested positive for A. abstrusus at molecular diagnosis. Multifocal encephalitis and meningitis and glial nodules were the most common histopathological lesions found in mice inoculated with A. abstrusus. All cats shed first-stage larvae of A. abstrusus after ingestion of mice inoculated with this nematode. In this study, we provide information on the anatomical localization, histopathological alterations and rate of recovery of A. abstrusus L3 in mice, and confirm their infectivity to cats (definitive hosts) after feeding on infected mice (paratenic hosts). Data presented here add knowledge to further understand the biology of A. abstrusus in mice and underline the importance of mice as paratenic hosts of this nematode for the infection of cats.

22 October 2007 in Journal of Fish Diseases
Verified
Journal Article
Closed access
PDF file
HKH Kaltner
H Kaltner
MSM Stippl
M Stippl
MKMartin Knaus
Martin Knaus
MEMansour El-Matbouli
Mansour El-Matbouli

2 April 2021 in Parasite
Verified
Journal Article
Open access
PDF file
MKMartin Knaus
Martin Knaus
CBChristine Baker
Christine Baker
RARoberto Alva
Roberto Alva
EMElizabeth Mitchell
Elizabeth Mitchell
JIJennifer Irwin
Jennifer Irwin
CJChris Johnson
Chris Johnson
NexGard®Combo, a novel topical antiparasitic product for cats, combines the insecticide/acaricide esafoxolaner with the nematocide eprinomectin and cestodicide praziquantel. The efficacy of this combination product was evaluated against two common endoparasites of global occurrence in cats, the nematodeToxocara catiand the cestodeDipylidium caninum, in five controlled studies using naturally or experimentally infected cats with parasites of North American, South African or European origin. Cats evaluated in these studies harbored patent infection of the target parasite confirmed through a pre-treatment fecal examination. In each study, cats were allocated randomly to two groups of equal size (8 or 10 cats per group per study), one group treated with a placebo (mineral oil) and the other with NexGard®Combo. Both treatments were administered once as a spot-on at 0.12 mL per kg body weight to deliver the minimum label dosage (1.44 mg/kg esafoxolaner, 0.48 mg/kg eprinomectin, and 10.0 mg/kg praziquantel) to the NexGard®Combo-treated cats. To determine efficacy, geometric mean parasite counts seven to 12 days after treatment of placebo-treated (control) cats and NexGard®Combo-treated cats were compared. The efficacy of NexGard®Combo was 98.8% and 100% against adultT. catiin two studies; and 98.0%, 98.3% and 93.2% againstD. caninumin three studies.No adverse events related to treatment were observed throughout the studies. These studies demonstrate high efficacy against these major feline endoparasites and excellent acceptability of the novel topical antiparasitic combination of esafoxolaner, eprinomectin and praziquantel.

1 January 2020 in Veterinary Parasitology
Verified
Journal Article
Open access
MKMartin Knaus
Martin Knaus
MVMartin Visser
Martin Visser
SMSandra Mayr
Sandra Mayr
SRSteffen Rehbein
Steffen Rehbein
• Broadline® is 100 % effective against Troglostrongylus brevior in cats. • A treatment has beneficial effects on pathology and health status of the cats.

2 April 2021 in Parasite
Verified
Journal Article
Open access
PDF file
MKMartin Knaus
Martin Knaus
BCBalázs Capári
Balázs Capári
MSMirjam Szabó
Mirjam Szabó
KKKatrin Kley
Katrin Kley
CJChris Johnson
Chris Johnson
The therapeutic efficacy against notoedric mange of a topical combination of esafoxolaner, eprinomectin and praziquantel (Nexgard® Combo, Boehringer Ingelheim) was evaluated in a masked, controlled clinical study including 14 cats with natural or induced Notoedres cati infestation. Cats were allocated randomly to two groups of seven cats each, to be administered either mineral oil (placebo control) or NexGard® Combo. Each treatment was administered once as spot-on at 0.12 mL per kg body weight (representing the minimum label dosage of NexGard® Combo, i.e. 1.44 mg esafoxolaner, 0.48 mg eprinomectin, and 10.0 mg praziquantel per kg body weight). Live mites were counted in skin scrapings collected within seven days prior to and 14, 27/28, 42 and 56 days after treatment to calculate the percentage efficacy of NexGard® Combo based on the comparison of mean live mite counts of the two groups. Concurrently, mange lesions and clinical signs were scored to establish a clinical success valuation. No live mites were recovered from any NexGard® Combo-treated cats post-treatment, indicating 100% therapeutic efficacy following a single spot-on administration of the novel antiparasitic combination. The clinical success valuations in the NexGard® Combo-treated cats were 14.3%, 42.8%, 100% and 100% at 14, 27/28, 42 and 56 days after treatment, respectively. No health problems were observed throughout the study.

1 January 2020 in Veterinary Parasitology
Verified
Journal Article
Open access
MKMartin Knaus
Martin Knaus
PTPiyanan Taweethavonsawat
Piyanan Taweethavonsawat
TCTara Cheesman
Tara Cheesman
MVMartin Visser
Martin Visser
SRSteffen Rehbein
Steffen Rehbein
• Broadline® is highly effective against developing and adult A. ceylanicum hookworms in cats. • Treatment reduces the risk of transmission to other animals and zoonotic risk to humans.